STOCK TITAN

Icon Plc - $ICLR STOCK NEWS

Welcome to our dedicated page for Icon Plc news (Ticker: $ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icon Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icon Plc's position in the market.

Rhea-AI Summary
ICON plc (ICLR) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences
-
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) is recognized as a top-rated employer and leader in clinical trial innovation, earning accolades for its ESG efforts, employee satisfaction, and diversity practices. The company ranked 88th in TIME’s list of the World’s Best Companies of 2023 and received recognition on Forbes' World’s Best Employers and World’s Top Companies for Women lists. Additionally, ICON was awarded the Financial Times Leaders in Diversity Award and the Frost & Sullivan Institute’s '2023 Enlightened Growth Leadership Award'. The company's CEO, Steve Cutler, emphasized ICON's commitment to achieving ESG goals and creating an inclusive workplace. Furthermore, ICON's digital innovation, marketing campaigns, and employee contributions were also acknowledged through various industry awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
Rhea-AI Summary
ICON plc (ICLR) announced that Moody's Investors Service upgraded all of its instrument ratings to Baa3 with a stable outlook, reflecting a stronger credit profile and investment grade financial profile. The upgrade is attributed to ICON's good operating performance, conservative financial strategy, and risk management policies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) CFO to present at Jefferies London Healthcare Conference and Evercore HealthCONx Conference, with webcasts available on the Investor section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
-
News
Rhea-AI Summary
ICON plc reports Q3 2023 financial results with net business wins of $2.6 billion and revenue growth of 5.8% YoY. Adjusted EBITDA and adjusted earnings per share increased by 13.9% and 10% respectively. The company reaffirms its full-year 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
-
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) upgraded to investment grade credit rating of BBB- by S&P Global Ratings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
Rhea-AI Summary
ICON plc to release Q3 2023 financial results on October 25, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
ICON plc announces release of next generation Clinical Trial Tokenisation solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary
ICON plc partners with BARDA to conduct clinical trial for next generation COVID-19 vaccine candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
partnership clinical trial covid-19
Rhea-AI Summary
ICON plc CEO to present at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
conferences
Icon Plc

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

25.55B
81.31M
0.66%
101.49%
1.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Dublin 18

About ICLR

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.